Neuropace (NPCE)

• Market cap: $326M
• 1 day: -1.5%
• 5 days: 0.92%
• 1 month: 8%
• 3 months: -12.2%
• 6 months: -10.12%
• Year to date: -14.85%
• 1 year: 36.38%
• 5 years: -60.5%
• 10 years: -60.5%
• Sector: Healthcare
• Industry: Medical Devices

About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Employees: 209

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

4,264% more call options, than puts

Call options by funds: $35M | Put options by funds: $802K

100% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 23

62% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 13

9% more funds holding

Funds holding: 90 [Q1] → 98 (+8) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

4.89% less ownership

Funds ownership: 73.5% [Q1] → 68.62% (-4.89%) [Q2]

15% less capital invested

Capital invested by funds: $294M [Q1] → $251M (-$43.4M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15
• Avg. target: $15
• High target: $15

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Vik Chopra

$15

Overweight Maintained

13 Aug 2025